• Je něco špatně v tomto záznamu ?

Building new cardiac vasculature and myocardium: where are we at

V. Sedlakova, M. Ahumada, EJ. Suuronen, EI. Alarcon

. 2021 ; 36 (6) : 728-734. [pub] 20211101

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22019639

Grantová podpora
CPG-158280 CIHR - Canada

PURPOSE OF REVIEW: This review describes the latest advances in cell therapy, biomaterials and 3D bioprinting for the treatment of cardiovascular disease. RECENT FINDINGS: Cell therapies offer the greatest benefit for patients suffering from chronic ischemic and nonischemic cardiomyopathy. Rather than replacing lost cardiomyocytes, the effects of most cell therapies are mediated by paracrine signalling, mainly through the induction of angiogenesis and immunomodulation. Cell preconditioning, or genetic modifications are being studied to improve the outcomes. Biomaterials offer stand-alone benefits such as bioactive cues for cell survival, proliferation and differentiation, induction of vascularization or prevention of further cardiomyocyte death. They also provide mechanical support or electroconductivity, and can be used to deliver cells, growth factors or drugs to the injured site. Apart from classical biomaterial manufacturing techniques, 3D bioprinting offers greater spatial control over biomaterial deposition and higher resolution of the details, including hollow vessel-like structures. SUMMARY: Cell therapy induces mainly angiogenesis and immunomodulation. The ability to induce direct cardiomyocyte regeneration to replace the lost cardiomyocytes is, however, still missing until embryonic or induced pluripotent stem cell use becomes available. Cell therapy would benefit from combinatorial use with biomaterials, as these can prolong cell retention and survival, offer additional mechanical support and provide inherent bioactive cues. Biomaterials can also be used to deliver growth factors, drugs, and other molecules. 3D bioprinting is a high-resolution technique that has great potential in cardiac therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019639
003      
CZ-PrNML
005      
20220804135842.0
007      
ta
008      
220720s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/HCO.0000000000000905 $2 doi
035    __
$a (PubMed)34456252
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sedlakova, Veronika $u Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Building new cardiac vasculature and myocardium: where are we at / $c V. Sedlakova, M. Ahumada, EJ. Suuronen, EI. Alarcon
520    9_
$a PURPOSE OF REVIEW: This review describes the latest advances in cell therapy, biomaterials and 3D bioprinting for the treatment of cardiovascular disease. RECENT FINDINGS: Cell therapies offer the greatest benefit for patients suffering from chronic ischemic and nonischemic cardiomyopathy. Rather than replacing lost cardiomyocytes, the effects of most cell therapies are mediated by paracrine signalling, mainly through the induction of angiogenesis and immunomodulation. Cell preconditioning, or genetic modifications are being studied to improve the outcomes. Biomaterials offer stand-alone benefits such as bioactive cues for cell survival, proliferation and differentiation, induction of vascularization or prevention of further cardiomyocyte death. They also provide mechanical support or electroconductivity, and can be used to deliver cells, growth factors or drugs to the injured site. Apart from classical biomaterial manufacturing techniques, 3D bioprinting offers greater spatial control over biomaterial deposition and higher resolution of the details, including hollow vessel-like structures. SUMMARY: Cell therapy induces mainly angiogenesis and immunomodulation. The ability to induce direct cardiomyocyte regeneration to replace the lost cardiomyocytes is, however, still missing until embryonic or induced pluripotent stem cell use becomes available. Cell therapy would benefit from combinatorial use with biomaterials, as these can prolong cell retention and survival, offer additional mechanical support and provide inherent bioactive cues. Biomaterials can also be used to deliver growth factors, drugs, and other molecules. 3D bioprinting is a high-resolution technique that has great potential in cardiac therapy.
650    _2
$a biokompatibilní materiály $7 D001672
650    12
$a bioprinting $7 D062028
650    _2
$a lidé $7 D006801
650    _2
$a myokard $7 D009206
650    _2
$a kardiomyocyty $7 D032383
650    12
$a 3D tisk $7 D066330
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Ahumada, Manuel $u Center for Applied Nanotechnology $u School of Biotechnology, Faculty of Sciences, Universidad Mayor, Santiago, Chile
700    1_
$a Suuronen, Erik J $u BEaTS Research, Division of Cardiac Surgery, University of Ottawa Heart Institute $u Department of Cellular and Molecular Medicine
700    1_
$a Alarcon, Emilio I $u BEaTS Research, Division of Cardiac Surgery, University of Ottawa Heart Institute $u Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
773    0_
$w MED00001278 $t Current opinion in cardiology $x 1531-7080 $g Roč. 36, č. 6 (2021), s. 728-734
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34456252 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135836 $b ABA008
999    __
$a ok $b bmc $g 1823017 $s 1170882
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 36 $c 6 $d 728-734 $e 20211101 $i 1531-7080 $m Current opinion in cardiology $n Curr. Opin. Cardiol. $x MED00001278
GRA    __
$a CPG-158280 $p CIHR $2 Canada
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace